The FDA approved ENFLONSIA™, a preventive monoclonal antibody against respiratory syncytial virus (RSV) developed by MSD.
Once again, Equipo Ciencia participated in the clinical study in 3 centers in CABA, Córdoba and MDQ.
The trial allowed to demonstrate the efficacy and evaluate the safety of this new strategy to prevent lower respiratory tract disease caused by RSV in newborns and infants.
Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory tract infection hospitalizations by more than 84% and 90%, respectively, over 5 months.
El criterio principal de valoración de eficacia del ensayo fue la reducción en la incidencia de infecciones respiratorias bajas con asistencia médica (MALRI) asociadas al VSR en comparación con placebo, hasta el día 150 (5 meses) después de la dosis, fue del 60,4 % (IC del 95 %: 44,1; 71,9; p < 0,001).
The incidence of adverse events (AEs) and serious AEs was comparable between the Clesrovimab and placebo groups, and no treatment-related or RSV-related deaths occurred during the study.
We are proud to have been part of this breakthrough!
See MSD Press Release.
